

Cancer screening and diagnosis with exosomes

“The exosomes are very small vesicles with a nanoparticle size, that are released by all the cells but in particular by the tumoral tissues. They can be caught in the blood or other biological fluids in order to analyse the content searching for biomarkers for assay development for oncological patient’s screening or diagnostic monitoring”.

We have the mission to develop products that can help the clinician in the support of the oncological patient or in the identification of those patients that could have a neoplastic pathology. This is our mission, our wish to develop something that can help the patient as soon as possible.

The support of TLS is fundamental because it allows us to access technological platforms, services and infrastructures unaffordable for a micro start up like us. This kind of support given by TLS allows us to reach faster our objectives and to attract potential industrial and financial investors, that, in more occasions, highlighted the value that an incubator like TLS gives in the growth of a start up and in the reduction of the initial investment”.

In a prospect of 5-10 Years I foresee that the mission of Exosomics could extend to other indications, not only in the oncology field, but also in the sector of the regenerative medicine, of chronic-inflammatory diseases and neurobiology.

Davide Zocco - Head of Molecular Diagnostics Exosomics Siena SPA